Ulcerative colitis and Crohn's disease are the two forms of inflammatory bowel disease(IBD). The advent of biological drugs has significantly changed the management of these conditions. Skin manifestations are not...Ulcerative colitis and Crohn's disease are the two forms of inflammatory bowel disease(IBD). The advent of biological drugs has significantly changed the management of these conditions. Skin manifestations are not uncommon in IBD. Among the reactive lesions(immunemediated extraintestinal manifestations), erythema nodosum(EN) and pyoderma gangrenosum(PG) are the two major cutaneous ills associated with IBD, while psoriasis is the dermatological comorbidity disease observed more often. In particular, in the last few years, anti-tumor necrosis factor(TNF)-α agents have been successfully used to treat psoriasis, especially these kinds of lesions that may occur during the treatment with biological therapies. The entity of the paradoxical manifestations has been relatively under reported as most lesions are limited and a causal relationship with the treatment is often poorly understood. The reason for this apparent side-effect of the therapy still remains unclear. Although side effects may occur, their clinical benefits are undoubted. This article reviews the therapeutic effects of the two most widely used anti-TNF-α molecules, infliximab(a fusion protein dimer of the human TNF-α receptor) and adalimumab(a fully human monoclonal antibody to TNF-α), for the treatment of the major cutaneous manifestations associated with IBD(EN, PG and psoriasis).展开更多
目的:探讨结节性红斑(Erythema nodosum,EN)复发的有关因素。方法:将2016年1月—2022年6月在赣南医科大学第一附属医院诊断为EN的患者分为复发组(26例)和未复发组(59例),对其临床资料进行回顾性对比分析。采用χ^(2)检验及t检验比较2组...目的:探讨结节性红斑(Erythema nodosum,EN)复发的有关因素。方法:将2016年1月—2022年6月在赣南医科大学第一附属医院诊断为EN的患者分为复发组(26例)和未复发组(59例),对其临床资料进行回顾性对比分析。采用χ^(2)检验及t检验比较2组临床特征及实验室检验指标,并对其进行多因素Logistic回归分析;比较EN患者结核菌素纯蛋白衍生物(Purified protein derivative of tuberculin,PPD)试验与结核感染T细胞斑点试验(T cell spot test of tuberculosis infection,T-SPOT.TB)的结果。结果:EN的复发与发病部位(χ^(2)=8.137,P=0.004)、C反应蛋白(χ^(2)=5.412,P=0.020)、中性粒细胞数目(χ^(2)=8.485,P=0.014)有关;多因素Logistic回归分析显示,发病部位(OR=5.394,95%CI=1.744~16.689)、C反应蛋白偏高(OR=3.383,95%CI=1.006~11.375)为EN复发的独立危险因素(P<0.05);T-SPOT.TB结果阳性时抗结核治疗的复发率(10%)比PPD试验结果阳性的复发率(81.4%)低(P<0.05)。结论:EN的复发与发病部位、C反应蛋白、中性粒细胞数目有关;影响EN复发的独立危险因素为发病部位、C反应蛋白;T-SPOT.TB与PPD试验联合应用有助于发现EN患者的结核感染,2项结果阳性时抗结核治疗的EN复发率较低。展开更多
文摘Ulcerative colitis and Crohn's disease are the two forms of inflammatory bowel disease(IBD). The advent of biological drugs has significantly changed the management of these conditions. Skin manifestations are not uncommon in IBD. Among the reactive lesions(immunemediated extraintestinal manifestations), erythema nodosum(EN) and pyoderma gangrenosum(PG) are the two major cutaneous ills associated with IBD, while psoriasis is the dermatological comorbidity disease observed more often. In particular, in the last few years, anti-tumor necrosis factor(TNF)-α agents have been successfully used to treat psoriasis, especially these kinds of lesions that may occur during the treatment with biological therapies. The entity of the paradoxical manifestations has been relatively under reported as most lesions are limited and a causal relationship with the treatment is often poorly understood. The reason for this apparent side-effect of the therapy still remains unclear. Although side effects may occur, their clinical benefits are undoubted. This article reviews the therapeutic effects of the two most widely used anti-TNF-α molecules, infliximab(a fusion protein dimer of the human TNF-α receptor) and adalimumab(a fully human monoclonal antibody to TNF-α), for the treatment of the major cutaneous manifestations associated with IBD(EN, PG and psoriasis).
文摘目的:探讨结节性红斑(Erythema nodosum,EN)复发的有关因素。方法:将2016年1月—2022年6月在赣南医科大学第一附属医院诊断为EN的患者分为复发组(26例)和未复发组(59例),对其临床资料进行回顾性对比分析。采用χ^(2)检验及t检验比较2组临床特征及实验室检验指标,并对其进行多因素Logistic回归分析;比较EN患者结核菌素纯蛋白衍生物(Purified protein derivative of tuberculin,PPD)试验与结核感染T细胞斑点试验(T cell spot test of tuberculosis infection,T-SPOT.TB)的结果。结果:EN的复发与发病部位(χ^(2)=8.137,P=0.004)、C反应蛋白(χ^(2)=5.412,P=0.020)、中性粒细胞数目(χ^(2)=8.485,P=0.014)有关;多因素Logistic回归分析显示,发病部位(OR=5.394,95%CI=1.744~16.689)、C反应蛋白偏高(OR=3.383,95%CI=1.006~11.375)为EN复发的独立危险因素(P<0.05);T-SPOT.TB结果阳性时抗结核治疗的复发率(10%)比PPD试验结果阳性的复发率(81.4%)低(P<0.05)。结论:EN的复发与发病部位、C反应蛋白、中性粒细胞数目有关;影响EN复发的独立危险因素为发病部位、C反应蛋白;T-SPOT.TB与PPD试验联合应用有助于发现EN患者的结核感染,2项结果阳性时抗结核治疗的EN复发率较低。
